BMO Capital Markets recently announced an adjustment to its stock rating for Terns Pharmaceuticals, Inc., downgrading it from "Outperform" to "Market Perform."

At the same time, the institution lowered the target stock price from the previous $54 to $53. This rating adjustment reflects the market's cautious attitude toward the company's near-term development prospects. Although the target price was only slightly reduced by $1, the change in rating may affect investor confidence in the stock. Pharmaceutical stocks have recently been generally under dual pressure from R&D progress and market competition. Analysts pointed out that attention should be paid to the company's subsequent clinical trial data and commercialization process.